Q4 2024 Management View Moderna CEO Stéphane Bancel highlighted 2024 as a year of significant progress, with revenues reaching $3.2 billion. The company reduced operating expenses by $2.6 billion and ...

The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...

Health scientists and drug industry executives around the world are on alert after the confirmation of Robert F. Kennedy Jr., who spreads antivaccine misinformation and has often derided the ...

Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in ...

Norovirus is highly infectious and causing a lot of illness this winter. Several vaccine candidates are making their way through clinical trials.

Star portfolio manager Cathie Wood’s Ark Investment Management filed its 13F holdings report for the fourth quarter on Feb. 4 ...

Explore the truth behind false claims that Moderna's CEO confessed to creating a COVID-19 vaccine before the pandemic, and the context of his remarks on vaccine production.

Vaccines are helpful in protecting against the flu and COVID-19, but could they also play a role in the fight against cancer? Imagine a future where every cancer treatment is personalized to each ...

Today, a brief rundown of news involving Novartis and AbbVie, as well as updates from Biogen, Merck & Co. and Sanofi that you may have missed. Pioneers like Alnylam Pharmaceuticals have led the RNA ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

The S&P 500 fell 0.5% on Wednesday, Jan. 29, as the Federal Reserve held interest rates steady in a move widely expected by the financial markets.

Skepticism has continued to transform as the diseases the vaccines target appear to have been controlled — like the elimination of polio in the U.S. Ironically, these vaccine victories have ...